Certara, a provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through development, has released version 13 of its Simcyp Simulator, which permits the quantitative prediction of drug-drug interactions and pharmacokinetic-pharmacodynamic outcomes in virtual populations.

The latest platform strengthens Simcyp’s position as a provider of translation tools for connecting preclinical ADMET data to clinical outcomes using modeling and simulation.

Simcyp has extended its model repertoire for biologics by incorporating a full physiologically-based pharmacokinetic (PBPK) model for monoclonal antibodies and therapeutic proteins with significant practical applications. In addition, the inclusion of a non-linear plasma protein and red blood cell-binding facility in version 13 addresses a level of complexity regularly needed for modeling in the oncology arena. The integration of a novel sophisticated IVIVC tool to handle in vitro-in vivo correlations of dissolution for various solid oral dosage forms enhances the scope of the simulator in the divisions of formulation and pharmaceutics.